On July 10, Zai Lab rose 5.15% in regular trading, trading at HKD 16.13 per share, with turnover of HKD 158 million.

On the news front, the National Healthcare Security Administration recently announced that newly negotiated drugs added to the medical insurance catalog have been deployed across 310,000 designated medical institutions nationwide, benefiting over 12 million patient visits. The commercial insurance innovative drug catalog now covers more than 1,486 institutions. Notably, Zai Lab products previously appeared on the preliminary review list for medical insurance catalog inclusion.

The continued optimization of the payment environment on the policy side, combined with broader sector strength, triggered a notable rally across biotechnology stocks. Within the sector, 3SBio rose 6.12%, Innovent Biologics gained 4.46%, and Akeso advanced 3.96%, reflecting a clear sector-wide linkage effect. Broker research has highlighted that the medical insurance negotiation mechanism and commercial insurance catalog are jointly supporting genuine innovation, with innovative drug companies expected to benefit from expanded access and incremental commercial opportunities.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)